New Rule on Prescription Imports to Raise Drug Costs for Americans

A new rule set to take effect in January will prohibit individuals from importing prescription drugs, a move expected to drive up costs for millions of Americans who rely on sources like Canadian pharmacies. The policy, enacted by the Food and Drug Administration and Customs Border Protection, represents a reversal from previous stances and has been met with concern over its potential impact on affordability.

President Trump's administration had previously considered enacting this ban on October 22, but delayed the decision due to worries about the timing just before midterm elections. However, the delay is seen by critics as merely postponing an inevitable price increase for consumers.

Despite claims that the U.S. offers the world's lowest drug prices, data indicates that prescription drug costs in the United States are substantially higher, often triple the prices found in other developed nations. A recent Kaiser Family Foundation survey revealed that a record number of Americans are concerned about affording their medications, with nearly half reporting they have skipped doses or not filled prescriptions to manage costs.

For individuals like James Bovard, an author and patient, the ban directly impacts his ability to afford necessary treatment. Bovard, who relies on Lumigan eye drops for glaucoma, finds that the medication costs significantly more in the U.S. than in Canada. He has been purchasing the drops from a Canadian online pharmacy for approximately $71 per month, a fraction of the U.S. retail price of $265 per month. After turning 65 and becoming eligible for Medicare, his options for discounts in the U.S. diminish, and he faces a higher out-of-pocket expense under Medicare's coverage structure.

Bovard's experience highlights a common scenario for many Americans, particularly seniors, who utilize international pharmacies to lower their prescription drug expenses. These individuals often pay out-of-pocket, which in turn can reduce costs for government programs like Medicare. The Campaign for Personal Prescription Importation notes that savings are typical for Americans purchasing from licensed Canadian pharmacies.

Concerns about the safety of imported drugs are frequently raised by pharmaceutical lobbyists. However, the source points to recent recalls of contaminated eye drops manufactured in the U.S. as evidence that domestic production is not immune to safety issues. Conversely, Canadian pharmacies adhering to standards set by the Canadian International Pharmacy Association have historically maintained a strong safety record, arguably better than some major pharmaceutical companies that have faced significant penalties for illegal conduct. The Drug Enforcement Administration has also taken action against companies violating federal laws related to controlled substances, regardless of their origin.

While Bovard anticipates that the eventual patent expiration for Lumigan may bring down prices, he warns that millions of other Americans dependent on various medications could face severe financial hardship. Representatives from the Canadian International Pharmacy Association have stated that individuals are increasingly turning to them due to unaffordability in their home countries. Critics argue that the risks posed by drug imports are overstated, while the risk of pricing essential medications out of reach for patients is a more immediate and pressing concern.

The author concludes by advocating for the freedom to purchase necessary medications without government intervention, questioning the logic of banning purchases from Canadian pharmacies when similar transactions are legal domestically. The ban on personal prescription imports is set to take effect in January, with its full impact on American consumers yet to be determined.